Exubera®: Treatment of type 1 and type 2 diabetes

Drugs of the Future

Volumn 29, Issue 12, 2004, Pages 1206-1210

  Cox, S L ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; INSULIN ANTIBODY; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG APPROVAL; DRUG FORMULATION; EUROPE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; WEIGHT GAIN;

EID: 13544261624     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.12.865630     Document Type: Article

References (24)

1. Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27: 1047-53.
2. Cafalu, W.T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 2004, 27: 239-46.
3. Nektar Therapeutics Web Site, http://www.nektar.com.
4. Heinemann, L., Klappoth, W., Rave, K., Hompesch, B., Linkeschowa, R., Heise, T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000, 23: 1343-7.
5. Weiss, S.R., Cheng, S.L., Kourides, I.A., Gelfand, R.A., Landschulz, W.H. on behalf of the Inhaled Insulin Phase II Study Group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: A randomized controlled trial. Arch Intern Med 2003, 163: 2277-82.
6. Cherrington, A.D., Neal, D.W., Edgerton, D.S. et al. Inhalation of insulin in dogs. Assessment of insulin levels and comparison to subcutaneous injection. Diabetes 2004, 53: 877-81.
7. Quattrin, T., Belanger, A., Bohannon, N.J., Schwartz, S.L. on behalf of the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004, 27: 2622-7.
8. Skyler, J.S., Cefalu, W.T., Kourides, I.A. et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study. Lancet 2001, 357: 331-5.
9. Rosenstock, J., Cappelleri, J.C., Bolinder, B., Gerber, R.A. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004, 27: 1318-23.
10. Cefalu, W.T., Skyler, J.S., Kourides, U.A. et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001, 134: 203-7.
11. Bergenstal, R.M. Achieving target HbA1c in studies with inhaled insulin in type 2 diabetes. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 866.
12. Hollander, P.A, Blonde, L, Rowe, R. et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004, 27: 2356-62.
13. Cefalu, W.T. on behalf of the Exubera Phase III Study Group. Mealtime rapid-acing inhaled insulin (Exubera®) improves glycaemic control in patients with type 2 diabetes failing combination oral agents: A 3-month, randomised, comparative trial. 38th Eur Assoc Study Diabetes (Sept 1-5, Budapest) 2002, Abst 807.
14. Bergenstal, R. on behalf of the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: Results of a 3-month, randomised, comparative trial. 18th Int Diabetes Fed Cong (Aug 24-29, Paris) 2003, Abst 801.
15. Dreyer, M. Efficacy and 2-year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 114.
16. Skyler, J.S. Long-term, sustained efficacy, and safety of inhaled insulin after 4 years of continuous therapy. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 863.
17. Simonson, D.C., Turner, R.R., Hayes, J.R, Scranton, R.E., Testa, M.A. Improving quality of life in type 2 diabetes when Exubera® is added after failure on metformin: A multicenter, international trial. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 865.
18. Testa, M.A., Turner, R.R., Hayes, J.F., Scranton, R.E., Simonson, D.C. Satisfaction and quality of life with sulfonylurea plus either metformin or Exubera®: An international randomized phase 3 trial. 64th Ann Sci Sess Am Diabetes Assoc (June 4-8, Orlando) 2004, Abst 487-P.
19. Gerber, R.A., Cappelleri, J.C., Kourides, I.A., Gelfand, R.A. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes. A randomized controlled trial. Diabetes Care 2001, 24: 1556-9.
20. Freemantle, N., Blonde, L., Bounder, B. et al. Inhaled insulin leads to a greater potential acceptance of insulin therapy in patients with uncontrolled type 2 diabetes. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 862.
21. Blonde, L., Freemantle, N., Ross, S.A., Bounder, B., Gerber, R.A. The availability of inhaled insulin leads to improved health outcomes in patients with uncontrolled type 2 diabetes. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 861.
22. Heise, T., Tusek, C., Stephan, J.A., Krasner, A. et al. Postprandial glucose control unaffected by insulin antibodies associated with inhaled insulin. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 864.
23. Mudaliar, S., Henry, R.R., Fryburg, D.A. et al. Within-subject variability of inhaled insulin (Exubera®) versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus. 18th Int Diabetes Fed Cong (Aug 24-29, Paris) 2003, Abst 802.
24. Pfizer sees strong prospects from the industry's premier R&D pipeline and expanding new product opportunities. Pfizer Inc. Press Release 2004, Nov 30.